REFERENCES
- Duan CY, Poticha D, Stoeckli T, and others. Biochemical evidence of cross-resistance to stavudine (d4T) triphos-phate in purified HIV-1 reverse transcriptase (RT) derived from a zidovudine (AZT)-resistant isolate. ( Abstract 442)
- Costagliola, Descamps D, Valcez V, and others. Presence of thymidine-associated mutations and response to d4T, abacavir, and ddl in the control arm of the NARVAL ANRS 088 trial. ( Abstract 450)
- Shulman N, Shafer R, Winters M, and others. Genotypic predictors of virologic response to stavudine after zidovudine monotherapy (ACTG 302). ( Abstract 437)
- Cohen C, Graham N, St. Clair M, Hiran, Rinehart A. Viro-logic suppression from different thymidine analogue (TA)-containing HAART regimen sequencing strategies: VIRA3001. ( Abstract 444)
- Lanier ER, Hellmann N, Scott J, and others. Determination of a clinically relevant phenotypic resistance "cutoff" for abacavir using the PhenoSense assay. (Abstract 254)
- Miller MD, Margot NA, Schooley RT, McGowan I. Baseline and week 48 final phenotypic analysis of HIV-1 from pa-tients adding tenofovir disoproxil fumarate (TDF) therapy to background ART. ( Abstract 441)
- Feng J, Jeffrey J, Anderson K, Copeland W, Furman P. Mechanistic studies of dioxolane guanosine 5'-triphos-phate: Implications for efficacy, lack of cross-resistance and selectivity of DAPD. ( Abstract 306)
- Brun S, Kempf D, Isaacson J, and others. Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to ABT-378. ( Abstract 452)
- Bernstein B, Moseley J, Kempf D, and others. Absence of resistance to Kaletra (ABT-378/r) observed through 48 weeks of therapy in antiretroviral naive subjects. ( Abstract 453)
- Weinstock H, Zaidi I, Woods, and others. Prevalence of mutations associated with decreased antiretroviral drug susceptibility among recently and chronically HIV-1-in-fected persons in 10 US cities, 1997–99. ( Abstract 265)
- Little SJ, Routy JP, Daar ES, and others. Antiretroviral drug susceptibility and response to initial therapy among re-cently HIV-infected subjects in North America. ( Abstract 756)
- Simon V, Vanderhoeven J, Hurley A, and others. Preva-lence of drug-resistant HIV-1 variants in newly infected individuals during 1999–2000. ( Abstract 423)
- Daar E, Pitt JA, Nichols S, and others. Viral evolution in an untreated patient who acquired multi-drug-resistant HIV during primary infection. ( Abstract 427)
- Yerly S, Race E, Vora S, and others. HIV drug resistance and molecular epidemiology in patients with primary HIV infection. ( Abstract 754)
- Chaix ML, Harzic M, Masquelier B, and others. Prevalence of genotypic drug resistance among French patients in-fected during the year 1999. ( Abstract 755)
- Graham N, Peeters M, Vergiest W, Harrigan R, Larder B. The Virtual Phenotype is an independent predictor of clini-cal response. ( Abstract 524)
- Kempf D, Hsu A, Jiang P, and others. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients is highly correlated with virtual inhibitory quotient. ( Abstract 523)
- De Luca A, Antinori A, Cingolani A, and others. A prospec-tive, randomized study on the usefulness of genotypic resistance testing and the assessment of patient-reported adherence in unselected patients failing potent HIV therapy (ARGENTA): Final 6-month results. ( Abstract 433)
- Decamps D, Flandre P, Izopet J, and others. Genotypic resistance to zidovudine (ZDV) and relationship to subse-quent virological response in NOVAVIR ANRS 073 trial. ( Abstract 438)
- Tasker SA, Brodine SK, Wegner SA, and others. Clinical impact of baseline genotypic resistance. ( Abstract 436)